Published in Blood Weekly, June 4th, 2009
The final results from the PROPEL study were reported in early February and formed the basis of the Company’s New Drug Application (NDA), which was submitted to the U.S. Food and Drug Administration (FDA) in March 2009. The poster presentation at ASCO will include analyses of response rate and durability of response, as well as...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.